8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 29, 2026·SEC
Kura Oncology, Inc.(KURA)Earnings, Financials & Key Ratios
KURA•NASDAQ
$11.04
Price updated Jul 6, 2026
AboutKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.Show more
- Revenue$67M+25.2%
- EBITDA-$303M-57.3%
- Net Income-$279M-60.2%
- EPS (Diluted)-3.18-57.4%
- Gross Margin99.92%
- EBITDA Margin-448.41%-25.6%
- Operating Margin-449.94%-25.5%
- Net Margin-412.95%-27.9%
- ROE-94.82%-121.0%
KURA Price & Volume
Kura Oncology, Inc. (KURA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Milestone Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial binary outcome
Key Thesis Takeaways
- Kura Oncology remains in a high-risk, pre-commercial phase where financial sustainability is entirely dependent on volatile milestone payments rather than recurring product revenue.
- The company's aggressive R&D spending, which reached $65.3M in 2026Q1, continues to outpace its ability to generate consistent operating income, leading to a rapid depletion of its cash reserves.
- Investors should monitor the firm's ability to reach clinical milestones, as the current liquidity buffer of $39.1M suggests a high probability of future dilutive equity financing to support ongoing operations.
Verdict Logic
the company's cash position of $39.1M against quarterly operating losses of $78.8M indicates a precarious financial runway that necessitates further capital raises.
KURA Growth Metrics
Kura Oncology, Inc. (KURA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM5.37%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-61.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-59.52%
Return on Capital
10 Years-36.59%
5 Years-34.78%
3 Years-40.36%
Last Year-46.61%
KURA Recent Earnings
Kura Oncology, Inc. (KURA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.83+5.7%
$0.88
Rev
$18M-29.7%
$26M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.92-27.8%
$0.72
Rev
$17M-51.1%
$35M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.85-49.1%
$0.57
Rev
$21M-59.7%
$51M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.75-600.0%
$0.15
Rev
$15M-76.5%
$65M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.83vs $0.88+5.7% | $18Mvs $26M-29.7% |
| Q2 2026 | Mar 5, 2026 | $0.92vs $0.72-27.8% | $17Mvs $35M-51.1% |
| Q4 2025 | Nov 4, 2025 | $0.85vs $0.57-49.1% | $21Mvs $51M-59.7% |
| Q3 2025 | Aug 7, 2025 | $0.75vs $0.15-600.0% | $15Mvs $65M-76.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Kura Oncology, Inc. (KURA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.04 | $980.07M | -3.47 | 25.24% | -412.95% | -94.82% | — | |
| $4.57 | $290.48M | -3.87 | 0.78% | -44.79% | -147.8% | — | |
| $4.79 | $194.47M | 3.93 | 36.55% | -19.55% | -3.39% | — | |
| $37.39 | $2.22B | -5.25 | 48.03% | -639.84% | -34.11% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $189.99 | $40.39B | -31.93 | — | — | -83.22% | — |
Compare KURA vs Peers
Kura Oncology, Inc. (KURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KURA SEC Filings & Documents
Kura Oncology, Inc. (KURA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when KURA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KURA Frequently Asked Questions
Kura Oncology, Inc. (KURA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Kura Oncology, Inc.'s revenue?
Kura Oncology, Inc. (KURA) reported $71.6M in revenue for fiscal year 2025.
How fast is Kura Oncology, Inc. growing?
Kura Oncology, Inc. (KURA) grew revenue by 25.2% over the past year. This is strong growth.
Is KURA profitable?
Kura Oncology, Inc. (KURA) reported a net loss of $294.6M for fiscal year 2025.
Dividend & Returns
What is KURA's return on equity?
Kura Oncology, Inc. (KURA) has a return on equity (ROE) of -94.8%. Negative ROE indicates the company is unprofitable.
What is Kura Oncology, Inc.'s free cash flow?
Kura Oncology, Inc. (KURA) had negative free cash flow of $84.5M in fiscal year 2025, likely due to heavy capital investments.